# To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection

> **NCT06561594** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Idiopathic Hypogonadotropic Hypogonadism

## Interventions

- **DRUG:** recombinant human follicle-stimulating hormone-CTP Fusion protein injection
- **DRUG:** recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo

## Key facts

- **NCT ID:** NCT06561594
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-20
- **Primary completion:** 2024-11-23
- **Final completion:** 2026-12-23
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561594, "To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06561594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*